OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

drugsTreatmentApproved2023🇨🇳

Gumarontinib

aka Haiyitan

Gumarontinib is Haihe Biopharma's MET inhibitor, approved in China in 2023 for non-small-cell lung cancer with MET exon 14 skipping.